Eupraxia Pharmaceuticals (EPRX) Competitors $5.76 +0.17 (+3.04%) Closing price 04:00 PM EasternExtended Trading$5.74 -0.01 (-0.26%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. NAGE, OCS, AVXL, PROK, AKBA, IMTX, MNMD, GYRE, SANA, and MRVIShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Niagen Bioscience (NAGE), Oculis (OCS), Anavex Life Sciences (AVXL), ProKidney (PROK), Akebia Therapeutics (AKBA), Immatics (IMTX), Mind Medicine (MindMed) (MNMD), Gyre Therapeutics (GYRE), Sana Biotechnology (SANA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Niagen Bioscience Oculis Anavex Life Sciences ProKidney Akebia Therapeutics Immatics Mind Medicine (MindMed) Gyre Therapeutics Sana Biotechnology Maravai LifeSciences Niagen Bioscience (NASDAQ:NAGE) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Which has more risk and volatility, NAGE or EPRX? Niagen Bioscience has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Which has stronger valuation & earnings, NAGE or EPRX? Niagen Bioscience has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M7.53$8.55M$0.2144.81Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.78 Do insiders & institutionals believe in NAGE or EPRX? 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend NAGE or EPRX? Niagen Bioscience currently has a consensus price target of $13.42, indicating a potential upside of 42.61%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 90.97%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is NAGE or EPRX more profitable? Niagen Bioscience has a net margin of 15.24% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience15.24% 23.12% 15.53% Eupraxia Pharmaceuticals N/A -626.84%-118.31% Does the media favor NAGE or EPRX? In the previous week, Eupraxia Pharmaceuticals had 9 more articles in the media than Niagen Bioscience. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.51 beat Eupraxia Pharmaceuticals' score of 0.19 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNiagen Bioscience beats Eupraxia Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.02M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-6.7820.6375.7726.11Price / SalesN/A442.69544.74124.93Price / CashN/A44.6737.5461.24Price / BookN/A9.6212.876.30Net Income-$25.50M-$52.73M$3.29B$271.03M7 Day Performance-4.64%0.64%-0.26%-0.15%1 Month Performance11.20%6.31%3.84%6.41%1 Year Performance125.00%18.97%68.35%28.81% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.0677 of 5 stars$5.76+3.0%$11.00+91.0%+104.8%$201.02MN/A-6.7829News CoverageNAGENiagen Bioscience2.2083 of 5 stars$9.63+1.5%$13.42+39.4%N/A$767.99M$99.60M45.86120Positive NewsOCSOculis2.9062 of 5 stars$17.45-1.2%$35.75+104.9%+46.3%$761.87M$780K-6.542Gap UpAVXLAnavex Life Sciences3.8226 of 5 stars$8.78-2.0%$44.00+401.1%+51.8%$754.11MN/A-15.4040PROKProKidney3.582 of 5 stars$2.53-3.4%$6.25+147.0%+19.3%$744.53M$80K-4.443Positive NewsAKBAAkebia Therapeutics3.8063 of 5 stars$2.80-1.1%$6.75+141.1%+105.2%$742.39M$160.18M-16.47430Positive NewsIMTXImmatics2.8241 of 5 stars$6.03+0.5%$14.67+143.2%-37.2%$732.95M$168.65M-9.28260MNMDMind Medicine (MindMed)2.4876 of 5 stars$9.57-1.4%$26.50+176.9%+62.0%$728.16MN/A-6.2540Positive NewsGYREGyre Therapeutics1.4738 of 5 stars$7.54-0.7%$18.00+138.7%-46.2%$726.18M$105.76M754.7540Positive NewsSANASana Biotechnology3.0771 of 5 stars$3.04-1.9%$8.00+163.2%-16.6%$722.93MN/A-2.87380News CoverageAnalyst ForecastMRVIMaravai LifeSciences3.2116 of 5 stars$2.81-2.8%$5.22+85.7%-67.8%$717.56M$259.18M-2.07610Positive News Related Companies and Tools Related Companies Niagen Bioscience Competitors Oculis Competitors Anavex Life Sciences Competitors ProKidney Competitors Akebia Therapeutics Competitors Immatics Competitors Mind Medicine (MindMed) Competitors Gyre Therapeutics Competitors Sana Biotechnology Competitors Maravai LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts